Phase 4 Kidney Cancer Trial, Recruiting NCT07028125 Sponsor: Centre Francois Baclesse Condition: Kidney Cancer
Back to Kidney Cancer

Phase 4 Kidney Cancer Trial, Recruiting

NCT07028125
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are older than 18 years of age
  • People who have been diagnosed with advanced or spreading kidney cancer (called Renal Cell Carcinoma) that includes a specific type known as "clear-cell"
  • People who have not yet received any systemic (whole-body) treatment for their kidney cancer
  • People whose doctor has already decided, before the study begins, to treat them with the combination of cabozantinib and nivolumab as their first treatment for advanced kidney cancer, in line with locally approved guidelines
  • Women who could become pregnant must not be pregnant at the start of or during treatment, and must use effective contraception throughout treatment and for at least 5 months after treatment ends; sexually active participants and their partners must also use a barrier method of contraception (such as a condom) during this time
  • People who are enrolled in an appropriate social security system
  • People who have read and signed an informed consent form before any trial activities begin

Who may not be able to join:

  • People who the trial doctor believes are unable or unwilling to follow the study requirements
  • People who are currently taking part in another clinical trial or investigational program that could interfere with this study's treatment
  • People who have a known allergy or hypersensitive reaction to any ingredients in the study medications
  • People who have a medical reason why they cannot take the study medications
  • Women who are pregnant or currently breastfeeding
  • People who are unable to use digital tools (such as a smartphone or tablet)
  • People who are not free to make their own legal decisions, or who are under the supervision of a legal guardian

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: +33231455002

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Centre Francois Baclesse
Registry
ClinicalTrials.gov
Start date
1 October 2025
Est. completion
1 October 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Rate of patients with adjustment of treatments management

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov